Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
By J. Maertens, I. Raad, K. Marr, T. Patterson, D. Kontoyiannis, O. Cornely, E. Bow, G. Rahav, D. Neofytos, M. Aoun and 18 more. The Lancet, 2016
849 citations recorded by the source corpus.
Subfields: Epidemiology, Infectious Diseases, Ophthalmology
View Paper: https://www.semanticscholar.org/paper/7f2913b565908c2218ec0cb0bed0466ca6d945ca
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Infectious Diseases
Citations in the corpus
- ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients (2016, background): “As the full paper was published shortly after the meeting, and confirms the results, the provisional grading attributed during the meeting has been transformed into a definite grading in this manuscript.(51) Currently, amphotericin B deoxycholate is considered to have no role in the treatment of inv”
- Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. (2018, background): “patients To increase response and survival rate Isavuconazole 200 mg IV tid day 1e2, then 200 mg qd oral A I IIt IIt D III, if mould active azole prophylaxis fewer adverse effects than voriconazole [173,507,564,565]”
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016, result): “We recommend performing a bronchoscopy with bronchoalveolar lavage (BAL) in patients with a suspicion of IPA (strong recommendation; moderate-quality evidence).”
- Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (2019, background): “These definitions achieved their original aim in fostering communication and enabling comparison of study findings among those engaged in research into IFD of patients with cancer and recipients of hematopoietic stem cell transplants (HSCTs) or solid organ transplants (SOTs) [2, 3].”